Pay in 4 interest-free payments of $5.84 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
311 (4):C572-c582 123
Recent Developments In February 2026 , Pfizer announced positive Phase 2b trial results for its ultra-long-acting injectable GLP-1 (PF-08653944), demonstrating significant weight loss with monthly dosing
It found a 20% reduction in major adverse cardiovascular events - heart attacks, strokes, and cardiovascular death - with FDA-approved Wegovy in a population with established cardiovascular disease and overweight or obesity
Future research should therefore focus on well-designed prospective clinical studies, standardized patient selection criteria, and translational investigations integrating clinical and experimental data
-
These findings suggest that exendin 939 may be less likely to cause adverse effects associated with thermoregulation, such as hyperthermia or hypothermia, as observed with previous TRPV1 antagonists
